Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Armata Pharmaceuticals, Inc.(ARMP US)

$3.87+0.154.03%Ext:$4.68+0.8120.98%(Market Closed · 01:00:03 UTC)
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
CategorizedChronologicalBy Owner

Financials & Metrics

FinancialsChartingShort InterestEmployees
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Armata Pharmaceuticals, Inc.(ARMP US)

$3.87+0.154.03%Ext:$4.68+0.8120.98%(Market Closed · 01:00:03 UTC)
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
CategorizedChronologicalBy Owner

Financials & Metrics

FinancialsChartingShort InterestEmployees
ARMP US​
Ask AI
ARMP US​
Ask AI

Chronological SEC Filings

Chronological SEC Filings

Non-Ownership Filings(748)

Expand
  • 10-QQ3ended 30 Sept 202612 Nov
  • 8-K​​​​​​​​​​ ​ ​September 30, 2026​ ​ ​December 31, 2025​ ​ ​Assets​​​​​​​Current assets​​​​​​​Cash and cash equivalents​$18,317​$8,688​Prepaid expenses and other current assets​1,073​1,508​Other receivables​​3,209​​472​Total current assets​22,599​10,668​Property and equipment, net​10,799​12,194​Operating lease right-of-use asset​32,378​33,911​Intangible assets, net​​13,746​​13,746​Other long-term assets​4,956​6,363​Total assets​$84,478​$76,882​​​​​​​​​Liabilities and stockholders’ deficit​​​​​Accounts payable, accrued and other current liabilities​$8,607​$8,947​Convertible Loan, current​​94,309​​—​Term debt, current​​83,862​​—​Total current liabilities​186,778​8,947​Convertible Loan, non-current​​—​​153,860​Term debt, non-current​​43,299​​103,061​Operating lease liabilities, net of current portion​​25,452​​26,533​Deferred tax liability​​3,077​​3,077​Total liabilities​258,606​295,478​Total stockholders’ deficit​(174,128)​(218,596)​Total liabilities and stockholders’ deficit​$84,478​$76,882​12 Nov
  • 8-KOther Events23 Sep
  • 8-KRegulation FD Disclosure14 Sep
  • 10-QQ2ended 30 Jun 202612 Aug
  • 8-K​​​​​​​​​​ ​ ​June 30, 2026​ ​ ​December 31, 2025​ ​ ​Assets​​​​​​​Current assets​​​​​​​Cash and cash equivalents​$23,952​$8,688​Prepaid expenses and other current assets​673​1,508​Other receivables​​2,532​​472​Total current assets​27,157​10,668​Property and equipment, net​11,230​12,194​Operating lease right-of-use asset​32,884​33,911​Intangible assets, net​​13,746​​13,746​Other long-term assets​4,933​6,363​Total assets​$89,950​$76,882​​​​​​​​​Liabilities and stockholders’ deficit​​​​​Accounts payable, accrued and other current liabilities​$8,715​$8,947​Convertible Loan, current​​163,904​​—​Term debt, current​​77,580​​—​Total current liabilities​250,199​8,947​Convertible Loan, non-current​​—​​153,860​Term debt, non-current​​42,024​​103,061​Operating lease liabilities, net of current portion​​25,823​​26,533​Deferred tax liability​​3,077​​3,077​Total liabilities​321,123​295,478​Total stockholders’ deficit​(231,173)​(218,596)​Total liabilities and stockholders’ deficit​$89,950​$76,882​12 Aug
  • 8-KRegulation FD Disclosure20 Jul
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers20 Jul
  • 8-KRegulation FD Disclosure13 Jul
  • S-8Registration statement (employee benefit plan)10 Jul
  • 8-K/ADeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers24 Jun
  • 8-KOther Events23 Jun
  • 8-KSubmission of Matters to a Vote of Security Holders16 Jun
  • 10-QQ1ended 31 Mar 202613 May
  • 8-K​​​​​​​​​​ ​ ​March 31, 2026​ ​ ​December 31, 2025​ ​ ​Assets​​​​​​​Current assets​​​​​​​Cash and cash equivalents​$4,754​$8,688​Prepaid expenses and other current assets​1,145​1,508​Other receivables​​47​​472​Total current assets​5,946​10,668​Property and equipment, net​11,780​12,194​Operating lease right-of-use asset​33,395​33,911​Intangible assets, net​​13,746​​13,746​Other long term assets​4,933​6,363​Total assets​$69,800​$76,882​​​​​​​​​Liabilities and stockholders’ deficit​​​​​Accounts payable, accrued and other current liabilities​$9,228​$8,947​Total current liabilities​9,228​8,947​Convertible loan, non-current​​254,922​​153,860​Term debt, non-current​​87,976​​103,061​Operating lease liabilities, net of current portion​​26,183​​26,533​Deferred tax liability​​3,077​​3,077​Total liabilities​381,386​295,478​Total stockholders’ deficit​(311,586)​(218,596)​Total liabilities and stockholders’ deficit​$69,800​$76,882​13 May
  • 8-KRegulation FD Disclosure7 May
  • ARSAnnual report to security holders27 Apr
  • DEF 14ADefinitive proxy statement27 Apr
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers27 Apr
  • 8-KOther Events2 Apr

Ownership Filings(367)

Expand
  • Form 4Birx Deborah14 Jul
  • SC 13D/AArmata Pharmaceuticals, Inc.13 May
  • Form 4Gilmer Daniel B.28 Apr
  • Form 3Gilmer Daniel B.28 Apr
  • Form 4Kyme Pierre17 Mar
  • Form 4Birx Deborah17 Mar
  • Form 4Kramer Robin11 Mar
  • Form 4Kyme Pierre11 Mar
  • Form 4House David Duane11 Mar
  • Form 4PATTI JOSEPH M11 Mar
  • Form 4Peterson Todd C.11 Mar
  • Form 4Odysseas Kostas D11 Mar
  • Form 4Birx Deborah11 Mar
  • Form 4Schlesinger Sarah J.11 Mar
  • Form 4Haimovitz Jules11 Mar
  • SC 13D/AArmata Pharmaceuticals, Inc.26 Jan
  • SC 13D/AArmata Pharmaceuticals, Inc.12 Aug 2025
  • Form 4Birx Deborah14 Jul 2025
  • Form 4Kyme Pierre25 Apr 2025
  • Form 3/AKyme Pierre25 Apr 2025

Non-Ownership Filings(748)

Expand
  • 10-QQ3ended 30 Sept 202612 Nov
  • 8-K​​​​​​​​​​ ​ ​September 30, 2026​ ​ ​December 31, 2025​ ​ ​Assets​​​​​​​Current assets​​​​​​​Cash and cash equivalents​$18,317​$8,688​Prepaid expenses and other current assets​1,073​1,508​Other receivables​​3,209​​472​Total current assets​22,599​10,668​Property and equipment, net​10,799​12,194​Operating lease right-of-use asset​32,378​33,911​Intangible assets, net​​13,746​​13,746​Other long-term assets​4,956​6,363​Total assets​$84,478​$76,882​​​​​​​​​Liabilities and stockholders’ deficit​​​​​Accounts payable, accrued and other current liabilities​$8,607​$8,947​Convertible Loan, current​​94,309​​—​Term debt, current​​83,862​​—​Total current liabilities​186,778​8,947​Convertible Loan, non-current​​—​​153,860​Term debt, non-current​​43,299​​103,061​Operating lease liabilities, net of current portion​​25,452​​26,533​Deferred tax liability​​3,077​​3,077​Total liabilities​258,606​295,478​Total stockholders’ deficit​(174,128)​(218,596)​Total liabilities and stockholders’ deficit​$84,478​$76,882​12 Nov
  • 8-KOther Events23 Sep
  • 8-KRegulation FD Disclosure14 Sep
  • 10-QQ2ended 30 Jun 202612 Aug
  • 8-K​​​​​​​​​​ ​ ​June 30, 2026​ ​ ​December 31, 2025​ ​ ​Assets​​​​​​​Current assets​​​​​​​Cash and cash equivalents​$23,952​$8,688​Prepaid expenses and other current assets​673​1,508​Other receivables​​2,532​​472​Total current assets​27,157​10,668​Property and equipment, net​11,230​12,194​Operating lease right-of-use asset​32,884​33,911​Intangible assets, net​​13,746​​13,746​Other long-term assets​4,933​6,363​Total assets​$89,950​$76,882​​​​​​​​​Liabilities and stockholders’ deficit​​​​​Accounts payable, accrued and other current liabilities​$8,715​$8,947​Convertible Loan, current​​163,904​​—​Term debt, current​​77,580​​—​Total current liabilities​250,199​8,947​Convertible Loan, non-current​​—​​153,860​Term debt, non-current​​42,024​​103,061​Operating lease liabilities, net of current portion​​25,823​​26,533​Deferred tax liability​​3,077​​3,077​Total liabilities​321,123​295,478​Total stockholders’ deficit​(231,173)​(218,596)​Total liabilities and stockholders’ deficit​$89,950​$76,882​12 Aug
  • 8-KRegulation FD Disclosure20 Jul
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers20 Jul
  • 8-KRegulation FD Disclosure13 Jul
  • S-8Registration statement (employee benefit plan)10 Jul
  • 8-K/ADeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers24 Jun
  • 8-KOther Events23 Jun
  • 8-KSubmission of Matters to a Vote of Security Holders16 Jun
  • 10-QQ1ended 31 Mar 202613 May
  • 8-K​​​​​​​​​​ ​ ​March 31, 2026​ ​ ​December 31, 2025​ ​ ​Assets​​​​​​​Current assets​​​​​​​Cash and cash equivalents​$4,754​$8,688​Prepaid expenses and other current assets​1,145​1,508​Other receivables​​47​​472​Total current assets​5,946​10,668​Property and equipment, net​11,780​12,194​Operating lease right-of-use asset​33,395​33,911​Intangible assets, net​​13,746​​13,746​Other long term assets​4,933​6,363​Total assets​$69,800​$76,882​​​​​​​​​Liabilities and stockholders’ deficit​​​​​Accounts payable, accrued and other current liabilities​$9,228​$8,947​Total current liabilities​9,228​8,947​Convertible loan, non-current​​254,922​​153,860​Term debt, non-current​​87,976​​103,061​Operating lease liabilities, net of current portion​​26,183​​26,533​Deferred tax liability​​3,077​​3,077​Total liabilities​381,386​295,478​Total stockholders’ deficit​(311,586)​(218,596)​Total liabilities and stockholders’ deficit​$69,800​$76,882​13 May
  • 8-KRegulation FD Disclosure7 May
  • ARSAnnual report to security holders27 Apr
  • DEF 14ADefinitive proxy statement27 Apr
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers27 Apr
  • 8-KOther Events2 Apr

Ownership Filings(367)

Expand
  • Form 4Birx Deborah14 Jul
  • SC 13D/AArmata Pharmaceuticals, Inc.13 May
  • Form 4Gilmer Daniel B.28 Apr
  • Form 3Gilmer Daniel B.28 Apr
  • Form 4Kyme Pierre17 Mar
  • Form 4Birx Deborah17 Mar
  • Form 4Kramer Robin11 Mar
  • Form 4Kyme Pierre11 Mar
  • Form 4House David Duane11 Mar
  • Form 4PATTI JOSEPH M11 Mar
  • Form 4Peterson Todd C.11 Mar
  • Form 4Odysseas Kostas D11 Mar
  • Form 4Birx Deborah11 Mar
  • Form 4Schlesinger Sarah J.11 Mar
  • Form 4Haimovitz Jules11 Mar
  • SC 13D/AArmata Pharmaceuticals, Inc.26 Jan
  • SC 13D/AArmata Pharmaceuticals, Inc.12 Aug 2025
  • Form 4Birx Deborah14 Jul 2025
  • Form 4Kyme Pierre25 Apr 2025
  • Form 3/AKyme Pierre25 Apr 2025